Phase 4 Rare Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The participant must have been clinically diagnosed with CD55-deficient CHAPLE disease, as defined by the trial protocol.
• The participant's parent(s) or legal guardian(s) must be willing and able to attend clinic visits and follow all study procedures, including ensuring the participant completes the full series of meningococcal vaccinations required by the trial.
• The participant's parent(s) or legal guardian(s) must be willing to provide written consent for the participant to take part.
• The participant must currently have active CHAPLE disease, as defined by the trial protocol.

Who may not be able to join:

• People who have previously had a meningococcal infection.
• People who have not received a documented meningococcal quadrivalent (ACWY) vaccination before the screening visit, if the participant's parent(s) or legal guardian(s) are unwilling for the participant to receive this vaccination during the study.
• People who have not received documented vaccinations for Haemophilus influenzae and Streptococcus pneumoniae before the screening visit, where those vaccinations are recommended under local guidelines (confirm with trial site).
• People who have previously been treated with a complement inhibitor medication, as defined by the trial protocol (confirm with trial site).
• People who have another condition that causes low protein levels in the blood or a secondary condition affecting the lymphatic vessels of the intestine (confirm with trial site).

Important: Additional inclusion and exclusion criteria not listed here may also apply. Always verify eligibility with the trial site directly before applying.